Fewer TB patients in the Netherlands The key figures of the National Institute for Public Health and the Environment (RIVM) show that in 2017, the number of TB patients in the Netherlands fell below 800 TB patients for the first time
Hormone-disrupting effect methyl-, ethyl- and propylparaben still unclear RIVM has conducted literature research into the hormone-disrupting effects of the three most commonly used parabens (methyl-, ethyl- and propylparaben) and the exposure of consumers to these substa
Legislation on maximum permitted amount of synephrine in food supplements is desirable Harmful health effects of dietary supplements with high levels of synephrine, which are used to lose weight or improve sports performance, cannot be excluded.
RIVM develops a framework for a broader view of establishing food safety standards In Europe, strict requirements apply to food safety. Food safety standards are determined at international level.
Less meat and more tap water benefits health and the environment In the Netherlands, diets with a high environmental impact contain more meat and energy.
Update on RIVM report “Silicone breast implants in the Netherlands”, State of Affairs October 2017 In June 2016, RIVM published the results of a study on breast implants in the Netherlands.
RIVM to contribute to new Horizon2020 project on oceans and human health across Europe A new EU Horizon2020 project Seas, Oceans and Public Health in Europe (SOPHIE) will explore the complex interplay between the health of the marine environment and that of humans.
Dutch collaboration in One Health European Joint Programme (EJP) RIVM, Wageningen Bioveterinary Research (WBVR) and the Netherlands Centre for One Health (NCOH) are involved in a recently granted One Health European Joint Programme which will start in January 20
Survey health complaints of women with a silicone breast implant This report provides a broad overview of the health complaints experienced by women with silicone breast implants in the Netherlands.
Efficiency and transparency of clinical drug trials must improve The efficiency and transparency of clinical drug trials in the Netherlands must improve. That concludes Sander van den Bogert in his PhD thesis ‘Trials & Tribulations.